Canadian liver journal最新文献_第10页

COVID-19 mRNA vaccines and their applications in chronic liver diseases. COVID-19 mRNA疫苗及其在慢性肝病中的应用

Canadian liver journal Pub Date : 2021-04-29 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0001

Julie H Zhu

引用次数: 0

The effects of binge drinking on healthy and diseased livers. 酗酒对健康和患病肝脏的影响。

Canadian liver journal Pub Date : 2021-04-29 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0037

Colin Rumbolt, Gerald Y Minuk

引用次数: 0

Autoimmune post-infantile giant cell hepatitis: a case report and review of the literature. 婴儿后自身免疫性巨细胞肝炎1例报告及文献复习

Canadian liver journal Pub Date : 2021-04-29 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0024

Yasi Xiao, Zu-Hua Gao, Marc Deschenes

引用次数: 2

Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada. 加拿大安大略省用于治疗丙型肝炎的直接作用抗病毒药物的处方趋势。

Canadian liver journal Pub Date : 2021-02-24 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0025

Mina Tadrous, Kate Mason, Zoë Dodd, Mary Guyton, Jeff Powis, Daniel McCormack, Tara Gomes

{"title":"Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada.","authors":"Mina Tadrous, Kate Mason, Zoë Dodd, Mary Guyton, Jeff Powis, Daniel McCormack, Tara Gomes","doi":"10.3138/canlivj-2020-0025","DOIUrl":"10.3138/canlivj-2020-0025","url":null,"abstract":"Background: Direct-acting antivirals (DAA) offer an opportunity to cure hepatitis C. Reimbursement for DAAs has changed on two occasions since their inclusion on the Ontario public formulary. Whether these changes have appreciably modified prescribing patterns and increased access to DAAs is unknown.Methods: We conducted a repeated cross-sectional study of DAA reimbursement by the Ontario Public Drug Programs from January 1, 2012, to December 31, 2018, to summarize the use of DAAs in Ontario and describe changes in DAA prescribing physician specialties over this period. We measured the total number of users quarterly. Results are reported overall and by prescriber type.Results: A total of 27,116 individuals received a publicly funded prescription for a DAA from the first quarter (Q1) of 2012 to the fourth quarter (Q4) of 2018. Nearly two-thirds (n = 17,813; 65.7%) of all DAAs were prescribed by gastroenterologists, hepatologists, or infectious disease specialists. Use of DAAs over time appears to have had three major phases in uptake: (1) the introduction of DAA treatments on the Ontario public drug formulary as a prior authorization benefit in Q1 2015, (2) expanded listing of all DAAs as limited-use products on the formulary in Q1 2017, and (3) the introduction of newer DAAs in Q2 2018.Conclusions: Changes in listing of these agents had a direct impact on the use of DAAs overall. Generally, broader listing expanded access but did not appear to shift utilization patterns to primary care prescribers. Further understanding of who is not receiving treatment is needed.","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"4 1","pages":"51-58"},"PeriodicalIF":0.0,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203166/pdf/canlivj-2020-0025.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40415164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HBV coinfection and in-hospital outcomes for COVID-19: a systematic review and meta-analysis. HBV合并感染与COVID-19住院结局:系统回顾和荟萃分析

Canadian liver journal Pub Date : 2021-02-24 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0029

Julie H Zhu, Kevork M Peltekian

{"title":"HBV coinfection and in-hospital outcomes for COVID-19: a systematic review and meta-analysis.","authors":"Julie H Zhu, Kevork M Peltekian","doi":"10.3138/canlivj-2020-0029","DOIUrl":"https://doi.org/10.3138/canlivj-2020-0029","url":null,"abstract":"Background: Since December 2019, there are 30 million confirmed cases of a novel coronavirus disease (COVID-19) secondary to severe acute respiratory syndrome coronavirus 2. As of 2020, hepatitis B virus (HBV) affects more than 200 million people worldwide. Both are caused by viral agents. The short-term mortality rate from COVID-19 is much higher than that of HBV.Objective: We sought to understand the impact of HBV coinfection on hospitalized patients with COVID-19.Search methods: Searches of the literature were conducted in the PubMed, Cochrane Library, and Embase electronic databases.Selection criteria: We included cohort studies and randomized studies with information on rates of mortality and intensive care unit (ICU) admission from individuals coinfected by HBV and COVID-19.Data collection and analysis: Data from six cohort studies with 2,015 patients were collected between January and April 2020, and the results were analyzed by meta-analysis.Main results: HBV coinfection did not lead to increased mortality or ICU admission rates among individuals hospitalized for COVID-19 (risk ratio 0.79, 95% CI 0.333-1.83, N = 2,015; adjusted OR = 0.79, 95% CI 0.31-1.98). During their hospital stay, coinfected patients did not appear to have an increased hospital length of stay or risk of hepatitis B reactivation.Conclusions: This systematic review and meta-analysis provides support that HBV is not a significant risk factor for serious adverse outcomes among patients hospitalized for COVID-19 infection.","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"4 1","pages":"16-22"},"PeriodicalIF":0.0,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203163/pdf/canlivj-2020-0029.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40414684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Cystic fibrosis liver disease in Newfoundland and Labrador: a prevalence study. 囊性纤维化肝病在纽芬兰和拉布拉多:一项流行研究。

Canadian liver journal Pub Date : 2021-02-24 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0012

Elizabeth Squirell, Joe Lockyer

{"title":"Cystic fibrosis liver disease in Newfoundland and Labrador: a prevalence study.","authors":"Elizabeth Squirell, Joe Lockyer","doi":"10.3138/canlivj-2020-0012","DOIUrl":"https://doi.org/10.3138/canlivj-2020-0012","url":null,"abstract":"Background: Liver disease in patients with cystic fibrosis (CF) is an understudied and increasingly common concern. The prevalence of cystic fibrosis liver disease (CFLD) in Canada has not been clearly established, although it is now the third leading cause of death among patients with CF. The current literature identifies a range in prevalence from 4% to 65%, which implies the need for further research. This study aimed to determine the prevalence of CFLD among adult patients with CF in Newfoundland and Labrador.Methods: Charts of patients with CF from the St. John's, Newfoundland, CF clinics were reviewed retrospectively for the presence of elevated liver enzymes, imaging or biopsy of the liver, and other etiologies of liver disease. Prevalence was determined for patients meeting the criteria for CFLD in the population as a whole and for those who had undergone all pertinent investigations.Results: The diagnostic guidelines for CFLD were met in 14 of 57 cases (24.6% prevalence). Severe CFLD was present in 9 patients (15.8%). Among all patients with CF, 33 (57.9%) had isolated liver enzyme elevation. Eleven patients had not had the requisite imaging performed for accurate diagnosis. Among the subset who had undergone imaging, the prevalence of CFLD was 30%.Conclusions: This study attempted to fill the gap in Canadian CFLD prevalence data by examining the population with CF in Newfoundland and Labrador. The prevalence of CFLD was found to be between 25% and 30%. More accurate determination of prevalence could be done with future cross-sectional or prospective studies.","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"4 1","pages":"33-37"},"PeriodicalIF":0.0,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203160/pdf/canlivj-2020-0012.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40414685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Striving toward hepatitis C elimination in the era of COVID-19. 在COVID-19时代努力消除丙型肝炎。

Canadian liver journal Pub Date : 2021-02-24 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0027

Charlotte Lanièce Delaunay, Zoë R Greenwald, Nanor Minoyan, Andreea Adelina Artenie, Dahn Jeong, Gayatri Marathe, Yasmin A Saeed, Gillian Kolla, Rasika D Kunden, Chisom Ifeoma Adaeze Okwor, Hannah L Wallace, Andrew Mendlowitz, Ching-Hsuan Liu, Sabrina Mazouz, Simmone D'souza, Catia Taniela Perciani, Marylin Rheault, Michael A Palmer, Adam Palayew, Mohamed N Abdelnabi, Evan B Cunningham

引用次数: 5

Achieving HCV micro-elimination in rural communities. 在农村社区实现微量消除丙型肝炎病毒。

Canadian liver journal Pub Date : 2021-02-24 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0022

Shannon J Brown, Linh T Cosgrove, Samuel S Lee

引用次数: 0

Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease. 瞬态弹性成像和 APRI 在评估小儿囊性纤维化肝病中的作用。

Canadian liver journal Pub Date : 2021-02-24 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0008

Jessica P Woolfson, Richard A Schreiber, Shraavan Raveendran, Mark Chilvers, Collin Barker, Orlee R Guttman

{"title":"Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease.","authors":"Jessica P Woolfson, Richard A Schreiber, Shraavan Raveendran, Mark Chilvers, Collin Barker, Orlee R Guttman","doi":"10.3138/canlivj-2020-0008","DOIUrl":"10.3138/canlivj-2020-0008","url":null,"abstract":"Background: Diagnosis and monitoring of cystic fibrosis liver disease (CFLD) is challenging. Transient elastography (TE) is a rapid, non-invasive method for assessing liver fibrosis. Its role in detecting fibrosis in CFLD has only begun to be explored. The aspartate aminotransferase to platelet ratio index (APRI) has been validated as a predictor of hepatic fibrosis in other chronic liver diseases. The purpose of this study was to assess the utility of APRI and TE in identifying liver fibrosis in pediatric CF patients.Methods: Patients aged 2-18 years were recruited from the British Columbia Children's Hospital CF clinic. Patients were determined to have CFLD using standard criteria. Charts were reviewed, and each patient underwent TE.Results: Of the 55 patients included in the study (50.9% male, mean age 11.6 y), 22 (40%) had CFLD. All mean liver enzymes were higher in the CFLD group, notably alanine transaminase (p = 0.031). Mean liver stiffness (LS) and APRI were also higher in the CFLD group (LS: 5.9 versus 4.5 kPa, p = 0.015; APRI: 0.40 versus 0.32, p = 0.119). Linear regression showed a mild positive association between the two (r 2 = 0.386).Conclusions: TE values were higher among CFLD patients and correlated with APRI values, suggesting that these tools may have clinical applications for identifying and following this population. Further research is needed on a larger scale to determine the relative value and clinical utility of TE and APRI among patients with CFLD.","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"4 1","pages":"23-32"},"PeriodicalIF":0.0,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203161/pdf/canlivj-2020-0008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40415162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Judging the value of ammonia measurement on lactulose dosing: Apples and oranges? 判断氨测量对乳果糖剂量的价值:苹果和橙子?

Canadian liver journal Pub Date : 2021-02-24 eCollection Date: 2021-01-01 DOI: 10.3138/canlivj-2020-0036

Christopher F Rose, Rajiv Jalan

引用次数: 1